Related Experiment Video
Updated: Jul 1, 2026

Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis
Published on: July 3, 2015
Receptor trafficking controls weak signal delivery: a strategy used by c-Met for STAT3 nuclear accumulation
Stéphanie Kermorgant1, Peter J Parker
1Department of Tumour Biology, Cancer Research UK Clinical Centre, Bart's and the London Queen Mary's School of Medicine and Dentistry, London EC1M 6BQ, England, UK.
Abstract:
C-Met, the receptor of hepatocyte growth factor (HGF), through overexpression or mutation, is a major protooncogene that provides an attractive molecular target for cancer therapy. HGF/c-Met-induced tumorigenesis is dependent, in part, on the transcription factor and oncogene signal transducer and activator of transcription 3 (STAT3), which is believed to be activated by the receptor at the plasma membrane and then to travel to the nucleus where it acts. We demonstrate that although the robust signal to STAT3 elicited from the cytokine oncostatin-M does indeed support this mechanism of STAT3 action, for the weaker STAT3 signal emanating from c-Met, the activated receptor itself needs to be delivered to a perinuclear endosomal compartment to sustain phosphorylated STAT3 in the nucleus. This is signal specific because c-Met-induced extracellular signal-regulated kinase nuclear accumulation does not require receptor trafficking to the perinuclear compartment. This response is triggered from peripheral endosomes. Thus, control of growth factor receptor traffic determines the nature of the signal output, providing novel opportunities for intervention.
Insights
Cancer therapy targeting C-Met requires understanding its signaling pathways. C-Met receptor trafficking to perinuclear endosomes sustains STAT3 activation in the nucleus, a novel finding for cancer intervention.
Area of Science:
- Oncology
- Molecular Biology
- Cell Signaling
Background:
- C-Met is a protooncogene and a key target in cancer therapy.
- Hepatocyte growth factor (HGF)/c-Met signaling drives tumorigenesis partly via Signal Transducer and Activator of Transcription 3 (STAT3).
- STAT3 activation is typically thought to occur at the plasma membrane, followed by nuclear translocation.
Purpose of the Study:
- To investigate the mechanism of STAT3 activation downstream of c-Met signaling.
- To determine the role of receptor trafficking in signal transduction.
- To explore novel therapeutic intervention points in cancer signaling.
Main Methods:
- Cellular signaling analysis
- Confocal microscopy to track receptor localization
- Investigating STAT3 and extracellular signal-regulated kinase (ERK) nuclear accumulation
Main Results:
- While robust STAT3 activation by oncostatin-M follows the canonical pathway, weaker STAT3 signals from c-Met require receptor trafficking to perinuclear endosomes.
- Sustained STAT3 phosphorylation in the nucleus depends on this perinuclear localization of the activated c-Met receptor.
- c-Met-induced nuclear accumulation of ERK is signal-specific and initiated from peripheral endosomes, unlike STAT3 signaling.
Conclusions:
- The trafficking route of growth factor receptors dictates the specific signal output.
- Perinuclear endosomal localization of c-Met is crucial for sustained STAT3 activation in the nucleus.
- Controlling growth factor receptor traffic offers new strategies for cancer therapy.
Related Concept Videos
Regulation of Nuclear Protein Sorting
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
Amplifying Signals via Enzymatic Cascade
Nuclear Localization Signals and Import
The JAK-STAT Signaling Pathway
Signal Transduction: Overview
Typically, signal transduction involves three...

